Terms: = Head and neck cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
4 results:
1. Prognostic significance of ezh2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases ezh2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract] [Full Text] [Related]
3. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma.
He LR; Liu MZ; Li BK; Rao HL; Liao YJ; Guan XY; Zeng YX; Xie D
BMC Cancer; 2009 Dec; 9():461. PubMed ID: 20028503
[TBL] [Abstract] [Full Text] [Related]
